Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMG 714

Drug Profile

AMG 714

Alternative Names: HuMax anti-IL15; HuMax-IL-15; PRV-015

Latest Information Update: 28 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Developer Amgen; Celimmune
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coeliac disease
  • Discontinued Inflammation; Lymphoma; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 28 Apr 2019 No recent reports of development identified for preclinical development in Coeliac disease in USA (SC)
  • 19 Mar 2019 Provention Bio plans the phase IIb PROACTIVE trial for non-responsive Coeliac disease in the first half of 2020
  • 05 Nov 2018 Amgen and Provention Bio enters into a licensing and co-development agreement for AMG 714 for Coeliac disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top